Cas:119509-24-9 3-[(2S,4S,5R)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1H-pyridin-2-one manufacturer & supplier

Chemical Name:3-[(2S,4S,5R)-5,6-dichloro-2,4-dimethylhexanoyl]-4-hydroxy-5,6-dimethoxy-1H-pyridin-2-one

CAS.NO:119509-24-9

Synonyms:3-[(2S,4S,5R)-5,6-Dichloro-2,4-dimethylhexanoyl]-2-hydroxy-5,6-dimethoxy-4(1H)-pyridinone;AT5;3-[(2S,4S,5R)-5,6-DICHLORO-2,4-DIMETHYL-1-OXOHEXYL]-4-HYDROXY-5,6-DIMETHOXY-2(1H)-PYRIDINONE;Atpenin A5;4(1H)-Pyridinone, 3-[(2S,4S,5R)-5,6-dichloro-2,4-dimethyl-1-oxohexyl]-2-hydroxy-5,6-dimethoxy-

Molecular Formula:C₁₅H₂₁Cl₂NO₅

Molecular Weight:366.237

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:532.6±50.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.534

PSA:88.62000

Exact Mass:365.079681

LogP:-0.80

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-[(2S,4S,5R)-5,6-Dichloro-2,4-dimethylhexanoyl]-2-hydroxy-5,6-dimethoxy-4(1H)-pyridinone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4(1H)-Pyridinone, 3-[(2S,4S,5R)-5,6-dichloro-2,4-dimethyl-1-oxohexyl]-2-hydroxy-5,6-dimethoxy- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4(1H)-Pyridinone, 3-[(2S,4S,5R)-5,6-dichloro-2,4-dimethyl-1-oxohexyl]-2-hydroxy-5,6-dimethoxy- Use and application,3-[(2S,4S,5R)-5,6-Dichloro-2,4-dimethylhexanoyl]-2-hydroxy-5,6-dimethoxy-4(1H)-pyridinone technical grade,usp/ep/jp grade.

Related News: The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production. 2-Bromo-2-methyl-N-(4-nitro-phenyl)-butyramide manufacturers The pivotal TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) phase III programme includes two trials, TULIP-1 and TULIP-2, that evaluated the efficacy and safety of anifrolumab versus placebo. (S)-2-(1-cyclohexyl-2-methyl-1H-benzo[d]imidazole-5-carboxamido)-3-(5-hydroxy-1H-indol-3-yl)propanoic acid suppliers The green light converts the companies’ accelerated approval to a full approval for endometrial cancer that’s not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and for patients whose tumors have progressed following prior treatment. (S)-2-{[1-(2-Azido-ethyl)-cyclopentanecarbonyl]-amino}-hept-6-enoic acid methyl ester vendor & factory.